YK-11

Research ChemicalPreliminary Research

Also known as: Myostine · SARM YK-11

A steroidal SARM that acts as both an androgen receptor partial agonist and a myostatin inhibitor, providing a dual mechanism for muscle growth.

Overview

YK-11 is a unique compound classified as a selective androgen receptor modulator (SARM) that also functions as a myostatin inhibitor — making it the only known compound with this dual mechanism. Structurally, YK-11 is a steroidal compound derived from DHT (dihydrotestosterone) that acts as a partial agonist of the androgen receptor. More importantly, YK-11 has been shown to increase follistatin expression in muscle cells, which in turn inhibits myostatin — the body's primary brake on muscle growth. This dual action of androgen receptor activation plus myostatin inhibition creates a powerful anabolic environment for muscle growth.

In cell studies, YK-11 induced more follistatin expression than DHT, suggesting superior muscle-building potential. It is popular in the performance enhancement community for its ability to promote lean muscle gains with potentially fewer androgenic side effects than traditional anabolic steroids.

Mechanism of Action

Partial agonist of the androgen receptor (AR), activating anabolic gene expression in muscle tissue. Simultaneously increases follistatin expression, which binds to and inhibits myostatin and activin A, removing the negative regulation of muscle growth. The dual AR agonism + myostatin inhibition provides synergistic anabolic effects.

Key Benefits

Enhanced muscle growth via dual mechanism
Myostatin inhibition through follistatin
Selective androgen receptor modulation
Potential for lean mass gains
May have fewer androgenic side effects than steroids
Increased follistatin expression

Potential Side Effects

Potential liver stress (oral form)
Testosterone suppression (PCT may be needed)
Joint dryness
Hair thinning (possible)
Limited long-term safety data

Common Stacks

This peptide is commonly combined with the following compounds for synergistic effects:

Follistatin 344MK-677Cardarine (GW-501516)IGF-1 LR3

Known Interactions

The following interactions have been documented for YK-11. Always consult a healthcare professional before combining compounds.

Use Caution (1)

Both have anabolic effects and potential liver impact. YK-11 is a myostatin inhibitor with steroidal structure, and oxandrolone is a 17-alpha alkylated steroid. Monitor liver enzymes.

Synergistic (1)

Follistatin 344Synergistic

Both inhibit myostatin through different mechanisms. Follistatin binds and neutralizes myostatin directly while YK-11 increases follistatin production. Powerful muscle growth stack.

View all compound interactions

Scientific References

Quick Reference

Typical Dose

5-20mg (oral) or 10-20mg (injectable)

Frequency

1x daily (oral) or 2x daily (injectable)

Route

Oral or subcutaneous injection

Half-Life

~6-10 hours

Cycle Length

4-8 weeks, followed by 4-8 weeks recovery with PCT

FDA Status

Research compound — not FDA approved. Not approved for human use. Banned by WADA.

Need to calculate dosing?

Use our reconstitution calculator to determine exact syringe measurements.

Open Calculator

This information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.

Related Peptides in Performance & Body Composition